The share

Inify Laboratories AB is listed on Euronext Growth Oslo since June 20th, 2022. All shares have equal rights and are freely transferable. Please follow the development of the Inify Laboratories share on Euronext Growth and view stock exchange releases at NewsWeb.
Euronext Growth
NewsWeb

Share information

Ticker code
Number of shares
Trading currency
Sector
ISIN
LEI code
INIFY
45,236,750
NOK
Health care
SE0017486103
549300306YYJ3BX3VB98

Shareholders

Inify Laboratories AB is listed on Euronext Growth Oslo under the ticker INIFY.
The list of total shares and the 20 largest shareholders is updated monthly, usually at month end. The last update was made on July 1st 2024. The company has a total of 45,236,750 outstanding shares.
Euronext Growth

20 largest shareholders

Number of shares heldOwnership (%)Shareholder
27 181 38660,09%Gallivant S.á.r.l.
4 691 41210,37%TAURI AS
1 964 7684,34%Günther-Hanssen, Sven
1 885 6834,17%Danske Bank A/S
1 382 2433,06%MP PENSJON PK
1 000 1512,21%BRAS KAPITAL AS
986 9502,18%MONSUN AS
673 9301,49%STAVLAND, BERNT
648 1671,43%STAVLAND, ANDERS
465 8591,03%Avanza Bank AB, MEGLERKONTO
425 8000,94%STAVLAND, PER
302 4570,67%SVEEN, KRISTIAN
283 5810,63%OLSEN, LARS EJNAR
189 7380,42%Skandinaviska Enskilda Banken AB
172 6970,38%Danske Bank A/S
166 2310,37%SKJELBRED, RUNE
139 9890,31%B STAVLAND HOLDING AS
104 9330,23%Nordnet Bank AB
81 0030,18%Bleikehidleren Invest AS
68 3000,15%STAVLAND, INGEBJØRG
2 421 4725,35%Others
45 236 750100,00%

Primary Insider Transactions

Information about primary insider transactions can be found under Investor news.

Dividend policy

The board of Inify Laboratories AB has not adopted a dividend policy since the Company considers itself to be in a growth phase, and therefore does not foresee that it will pay dividends in the near future. In deciding whether to propose a dividend and in determining the dividend amount, the Board of Directors will take into account legal restrictions as well as capital expenditure plans, financing requirements and maintaining the appropriate strategic flexibility.